{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021650","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.643042+00:00","generated_at":"2026-06-05T09:21:01.492929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MindMed reports FY2023 net loss $95.7M; Phase2b MM120 shows 7.6-point HAM-A reduction for GAD","bullets":["Cash and equivalents $99.7M vs $142.1M at Dec 2022; expected to fund operations into 2026.","Net loss $95.7M vs $56.8M in 2022; R&D expenses $52.1M (up $15.9M) driven by MM120 Phase 2b trial.","Phase 2b MM120 (100 µg) achieved 7.6-point HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response rate.","Plans End-of-Phase 2 FDA meeting H1 2024, Phase 3 MM120 GAD program start H2 2024; March 7 investor event for 12-week data.","Initiated Phase 1 trial of MM402 (R(-)-MDMA) for ASD in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021650","json":"https://secwatch.observer/filing/0000950170-24-021650.json","markdown":"https://secwatch.observer/filing/0000950170-24-021650.md","text":"https://secwatch.observer/filing/0000950170-24-021650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/0000950170-24-021650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/mnmd-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:21:01.492929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ced33c6b944d41a663418d8d89fc414f7a557ce3","claim":"Definium Therapeutics, Inc. reported financial results for year ended December 31, 2023.","evidence_excerpt":"MindMed Reports 2023 Financial Results and Business Updates --Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024-- --Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD)-- --Conference call to discuss year-end financial results at 8:00 a.m. EST--","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/0000950170-24-021650-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}